fludarabine has been researched along with Leukemia, Myelogenous, Aggressive Phase in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Calvert, L; Claxton, D; Durett, A; Giralt, S; Hamer, J; Kantarjian, H; Khouri, I; Liang, J; Talpaz, M; Tibbits, P | 1 |
1 other study(ies) available for fludarabine and Leukemia, Myelogenous, Aggressive Phase
| Article | Year |
|---|---|
Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autolog
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Cell Survival; Colony-Forming Units Assay; Combined Modality Therapy; Cyclophosphamide; Daunorubicin; Diploidy; Etoposide; Female; Genetic Markers; Hematopoietic Stem Cells; Humans; Idarubicin; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mitoxantrone; Neoplastic Stem Cells; Philadelphia Chromosome; Remission Induction; Survival Rate; Vidarabine; Whole-Body Irradiation | 1995 |